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Inflammation mediated by macrophages is increasingly found to play a central role in diseases and disorders that affect a myriad of
organs, prominent among these are diseases of the CNS. The neurotoxicant-induced, cuprizone model of demyelination is ideally suited
for the analysis of inflammatory events. Demyelination on exposure to cuprizone is accompanied by predictable microglial activation and
astrogliosis, and, after cuprizone withdrawal, this activation reproducibly diminishes during remyelination. This study demonstrates
enhanced expression of lymphotoxin  receptor (LtR) during the demyelination phase of this model, and LtR is found in areas
enriched with microglial and astroglial cells. Deletion of the LtR gene (LtR/) resulted in a significant delay in demyelination but also
a slight delay in remyelination. Inhibition of LtR signaling by an LtR–Ig fusion decoy protein successfully delayed demyelination in
wild-type mice. Unexpectedly, this LtR–Ig decoy protein dramatically accelerated the rate of remyelination, even after the maximal
pathological disease state had been reached. This strongly indicates the beneficial role of LtR–Ig in the delay of demyelination and the
acceleration of remyelination. The discrepancy between remyelination rates in these systems could be attributed to developmental
abnormalities in the immune systems of LtR/ mice. These findings bode well for the use of an inhibitory LtR–Ig as a candidate
biological therapy in demyelinating disorders, because it is beneficial during both demyelination and remyelination.
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Introduction
Tumor necrosis factor  (TNF) and lymphotoxin  (Lt) (also
known as TNF) are part of the large TNF superfamily of ligands
(Ware et al., 1995; Locksley et al., 2001; Zhang, 2004).
Membrane-bound or soluble TNF signals through TNFRI (also
p55) and TNFRII (also p75) to elicit a wide variety of signals in
many different cell types. Homotrimeric secreted Lt also signals
through TNFRI and TNFRII. Additionally, Lt can interact with
membrane-bound lymphotoxin  (Lt) to form a Lt hetero-
trimer, which is specific for lymphotoxin  receptor (LtR)
(Crowe et al., 1994; Ware et al., 1995). Signaling through LtR
causes the activation of TNF receptor-associated factor adaptor
molecules and induces signals through both the classical and al-
ternative nuclear factor-B pathways (Baud and Karin, 2001;
Dempsey et al., 2003).
The roles of TNF, Lt, TNFRI, and TNFRII have been ex-
tensively investigated in numerous rodent models of demyelina-
tion (Ruddle et al., 1990; Korner et al., 1997; Liu et al., 1998;
Probert et al., 2000; Arnett et al., 2001, 2003; Kassiotis and Kol-
lias, 2001). Although TNF and Lt are upregulated in multiple
sclerosis (MS) and are believed to play an important detrimental
role in the pathology of disease (Raine et al., 1998), inhibition of
TNF in patients leads to symptom exacerbation (van Oosten et
al., 1996; The Lenercept Multiple Sclerosis Study Group and The
University of British Columbia MS/MRI Analysis Group, 1999;
Robinson et al., 2001; Sicotte and Voskuhl, 2001), highlighting
the need for a comprehensive understanding of the role of TNF
family ligands and receptors in demyelinating disease.
Using inhibitors of LtR signaling to examine the role of LtR
in experimental autoimmune encephalomyelitis (EAE), one re-
port demonstrates that signaling by Lt heterotrimers is impor-
tant in demyelination (Gommerman et al., 2003). In these
studies, T-cell function was believed to be the primary target of
LtR–Ig. Although these results highlight the involvement of in-
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filtrating T cells in demyelination, the role of CNS-derived Lt
and LtR is not known. In addition, the capacity of signaling via
LtR to affect reparative remyelination has not been determined.
In the current investigation, we used the cuprizone model to
study the involvement of LtR in demyelination and remyelina-
tion. Cuprizone-induced demyelination and remyelination oc-
cur without T-cell involvement. We previously used the cupri-
zone model to demonstrate the detrimental nature of TNF and
Lt during demyelination and the beneficial effect of TNF in the
remyelination phase (Arnett et al., 2001; Plant et al., 2005). In the
present study, we demonstrate detrimental effects of LtR in
cuprizone-induced demyelination. In addition, we tested the ef-
ficacy of inhibitors of LtR signaling (LtR–Ig) and found sig-
nificant benefits of blocking the LtR pathway in both demyeli-
nation and remyelination phases of the model. These findings
strongly suggest that inhibition of LtR signaling in MS patients
may be a beneficial treatment option.
Materials and Methods
Animals. C57BL/6 mice were purchased from The Jackson Laboratory
(Bar Harbor, ME) and bred in house at the University of North Carolina
(UNC) animal facility. LtR/ mice (Futterer et al., 1998), previously
backcrossed to C57BL/6 for at least five generations, were imported from
the University of Chicago and bred in house at the UNC animal facility.
All procedures were conducted in accordance with National Institutes of
Health guidelines and were approved by the Institutional Animal Care
and Use Committee of UNC at Chapel Hill. All mice were 8 –10 weeks of
age before the start of cuprizone treatment.
Treatment of mice. Male LtR/ and C57BL/6 wild-type mice were
fed ad libitum 0.2% cuprizone [oxalic bis(cyclohexylidenehydrazide)]
(Sigma-Aldrich, St. Louis, MO) mixed into milled chow. Mice were
treated for 3, 3.5, 4, or 5 weeks to study the demyelination process. For
remyelination, mice were treated for 6 full weeks with cuprizone and
then were returned to a diet of normal pellet chow for 1, 2, 4, or 6 weeks
(7, 8, 10, or 12 weeks of total treatment). Untreated mice were main-
tained on a diet of normal pellet chow. This protocol was used for all
studies with the exception of those involving inhibitors of LtR signaling.
Two versions of murine LtR–IgG (LtR– human IgG and LtR–
mouse IgG) and their controls were kindly provided by Dr. J. Browning
(Biogen Idec, Cambridge, MA) and have been described previously
(Gommerman et al., 2003). Separate treatment paradigms were used for
studies using LtR–Ig fusion molecules. To study demyelination, mice
were intraperitoneally injected on day 1 and weekly thereafter with 5
mg/kg of either LtR– human IgG-1 Fc (LtR– hIg) or human IgG as a
control. To study remyelination, a posttreatment paradigm was used, in
which mice were treated with cuprizone for 6 full weeks. After 5 weeks
plus 2 d of cuprizone treatment (approximate height of demyelination)
and weekly thereafter out to 10 weeks, mice were given intraperitoneal
injections of either LtR–mouseIgG-1 (LtR–mIg) or matched control
mouse IgG-1, MOPC-21. This murine version of LtR–Ig has been
shown to be less antigenic in the mouse (J. Browning, personal
communication).
Tissue preparation and histopathological analysis. Paraffin-embedded
coronal brain sections were prepared from the fornix region of the cor-
pus callosum. Luxol fast blue–periodic acid Schiff (LFB–PAS) stained
sections were read by three double-blinded readers and graded on a scale
from 0 (complete myelination) to 3 (complete demyelination), as de-
scribed previously (Arnett et al., 2001; Plant et al., 2005).
Immunohistochemistry. Detection of mature oligodendrocytes and mi-
croglia/macrophages was performed by immunohistochemistry (IHC)
as described previously (Plant et al., 2005). Quantitative analyses of glu-
tathione S-transferase -positive (GST ) and Ricinus communis
agglutinin-1-positive (RCA-1 ) cells were restricted to a 0.033 mm 2 area
at midline corpus callosum. Only immunopositive cells with an observ-
able 4,6-diamidino-2-phenylindole-stained nucleus were included in
the quantification. Cell counts are averages of at least 9 and up to 14 mice
per time point. Myelinated fibers were detected by immunohistochem-
istry with a primary antibody to myelin basic protein (MBP) (diluted
1:1000; Sternberger Monoclonals, Lutherville, MD) followed by
fluorescein-conjugated anti-mouse IgG (Invitrogen, Carlsbad, CA) di-
luted 1:1000.
Dual in situ hybridization/immunohistochemical analysis. After cupri-
zone treatment, mice were perfused with RNase-free PBS and then 4%
paraformaldehyde. Brains were removed and incubated in fixative until
mounted for cryosectioning. Detection of mRNA for LtR was per-
formed by in situ hybridization (ISH) on free-floating brain cryosections
as described previously (Schmid et al., 2002). Briefly, 25 m sections
were hybridized overnight at 55°C with 33P-labeled riboprobes (10 7
cpm/ml). Excess probe was removed by successive washing with 0.03 M
NaCl, 0.003 M sodium citrate (2 SSC) containing 10 mM
-mercaptoethanol (-ME), followed by a 1 h incubation with ribonu-
clease at 37°C, a 2 h incubation at 55°C with 0.5 SSC, 50% formamide,
and 10 mM -ME, and finally by a 1 h incubation at 68 C in 0.1 SSC, 5
mM -ME and 5% sarcosyl. Myeloid cells and blood vessels were identi-
fied by their ability to bind biotinylated tomato lectin (Sigma, St. Louis,
MO), and visualized by standard streptavidin– horseradish peroxidase
methodology. Tissue sections were air dried onto superfrost plus slides
(Fisher Scientific, Hampton, NH) and coated with Ilford K-5 emulsion
(Polysciences, Warrington, PA). After 3 weeks, the emulsion-coated
slides were developed with Kodak D19 developer and fixative (Fisher
Scientific). Mayer’s hematoxylin was used to visualize cellular nuclei,
before dehydrating and preserving tissues sections under glass coverslips
with Permount. Emulsion grains were counted in six microscopy fields
per tissue section. Tissue sections from at least three mice were quanti-
fied. In each experiment, the basal (nonspecific) levels of grain counts
were determined from quantifying grains over ventricles and areas with-
out tissues. Induced expression was defined as threefold increase in
grains per microscopic field.
To discern the cell types that express LtR, the same tissue sections
were also immunolabeled with either tomato lectin to visualize micro-
glia, macrophages, and blood vessels or antibody to glial fibrillary acidic
protein (GFAP) to visualize astrocytes. All immunolabeled cells were
visualized by horseradish peroxidase staining (indicated by brown stain),
whereas cells expressing the LtR transcript were identified by black
grains generated by in situ hybridization. Blood vessels are readily distin-
guished from microglia and macrophages by their tubular structure.
Tomato lectin does not distinguish between microglia and macrophages.
Reverse transcription-PCR and quantitative real-time reverse
transcription-PCR. Total RNA was isolated from a dissected region of the
brain containing the corpus callosum of wild-type and LtR/ mice at
several points during and after cuprizone treatment. RNA isolation was
performed using the Qiagen (Valencia, CA) RNeasy kit under RNase-free
conditions. Reverse transcription (RT)-PCR for LIGHT (homologous to
lymphotoxins, exhibits inducible expression, and competes with herpes
simplex virus glycoprotein D for the herpes-virus entry mediator, a re-
ceptor expressed by T lymphocytes) was performed in 20 l reactions
using the following primers: 5 primer, CTGGCATGGAGAGTGTG-
GTA; 3 primer, GATACGTCAAGCCCCTCAAG.
TaqMan 5 nuclease quantitative real-time PCR assays were per-
formed using an ABI Prism 7900 sequence-detection system (Applied
Biosystems, Foster City, CA) in a 15 l reaction with universal master
mix (Invitrogen), 200 nM LtR target primers, and 100 nM probe.
LtR-specific primers were designed to span intron–exon junctions to differ-
entiate between cDNA and genomic DNA. The primers and probe used to
detect mouse LtR were as follows: 5 primer, GTACTCTGCCAGCCTG-
GCACAGAAGCCGAGGTCACAGATG; 3 primer, GGTATGGGGTTGA-
CAGCGGGCTCGAGGGGAGG; probe, 6-carboxyfluorescein (Fam)-
ACGTCAACTGTGTCCC-6-carboxytetramethylrhodamine (Tamra). The
primers and probe for mouse 18S ribosomal RNA were as follows: 5 primer,
GCTGCTGGCACCAGACTT; 3 primer, CGGCTACCACATCCAAGG;
probe, Fam-CAAATTACCCACTCCCGACCCG-Tamra. Thermal cycle pa-
rameterswereoptimizedto2minat50°C,2minat95°C,and40cyclescompris-
ing denaturation at 95°C for 15 s and annealing– extension at 56°C for 1.5
min. Reactions for 18S were performed alongside LtR during each ex-
periment and used to normalize for amounts of cDNA.
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Statistical analysis. Unpaired Student’s t tests were used to statistically
evaluate significant differences. Data are expressed as mean  SEM.
Results
LtR and LIGHT expression in the brain
To assess LtR expression in the cuprizone model, we performed
quantitative real-time RT-PCR to examine the level of LtR in
the corpus callosum and surrounding tissue in untreated and
cuprizone-treated mice. Low levels of LtR were detected in con-
trol untreated mice, whereas the levels of LtR rose moderately
throughout demyelination but were then reduced to baseline lev-
els during the remyelination phase (Fig. 1A).
Numerous strategies to detect LtR protein expression were
used, including immunoblot, IHC, and
flow cytometry. Unfortunately, high-
quality specific antibodies for the detec-
tion of mouse LtR by immunoblot or
IHC have not been reported, and we veri-
fied that existing antibodies do not work in
these assays. Although antibodies for flow
cytometry have been reported (Crowe et
al., 1994; Dejardin et al., 2002) for the stain-
ing of immune cells, flow cytometry of adult
brain cells is exceedingly challenging, and the
results appear suboptimal. Nonetheless, we
performed flow cytometry for microglial
(CD45CD11b) and astroglial (GFAP)
cell populations but were unable to obtain
specific staining for LtR by comparing
brain cells isolated from wild-type versus
LtR/ mice (supplemental Fig. 1, avail-
able at www.jneurosci.org as supplemental
material). Because of the lack of appropri-
ate serological reagents for the detection of
LtR protein, dual ISH/IHC analysis was
used to simultaneously define the regions
expressing the LtR transcript and iden-
tify cell populations present in these re-
gions during cuprizone treatment. LtR
mRNA expression was not detected in the
CNS of untreated mice (Fig. 1Bi). By 3
weeks of cuprizone treatment, a low level
of LtR expression was detected in the
corpus callosum region (Fig. 1Bii). By 5
weeks of treatment, robust expression of
LtR was detected throughout the corpus
callosum and slightly weaker expression
was detected in the striatal regions (Fig.
1Biii). By 3 weeks of cuprizone treatment,
there was an increase in the hypercellular-
ity of tomato lectin-stained cells in the cor-
pus callosum, and this level was further en-
hanced at the 5 week time point, consistent
with previous observations of robust micro-
gliosis (Fig. 1Cii,Ciii). Comparison of re-
gions with prominent microglia/macro-
phage accumulation at both time points
revealed that robust LtR ISH signal (black
grains) was enhanced in all regions with
strong induction of tomato lectin staining
indicated by the brown coloration. En-
hanced expression is defined as a threefold
increase from controls in grain density. In a
different set of samples, astrogliosis indi-
cated by increased brown color attributed to GFAP immunoreactiv-
ity was observed at the 3 week time point, and it also became much
more evident at the 5 week time point (Fig. 1Cv,Cvi). At the 3 week
time point, there was little colocalization of grains with GFAP cells
(Fig. 1Cv), but, at the 5 week time point (Fig. 1Cvi), GFAP cells
were accompanied by LtR grains. This indicates that, at the 3 week
time point before the dramatic increase in hypercellularity, LtR
expression is preferentially detected in regions enriched for lectin-
positive cells (Fig. 1, compare Cii, Cv). However, after 5 weeks of
treatment, LtR expression is most intense in areas enriched for
microglia/macrophages, but it is also increased in areas of
astrogliosis.
Figure 1. Upregulation of LtR during demyelination and inflammation. A, Upregulation of LtR during demyelination and
inflammation. Quantitative real-time RT-PCR analysis demonstrates an upregulation of LtR mRNA expression in wild-type mice
during cuprizone treatment (through week 5) and a decline to baseline levels during remyelination (weeks 7–10). B, Localization
of LtR mRNA by ISH during cuprizone treatment. At the level of autoradiogram analysis, LtR mRNA expression is not detected
by in situ hybridization in brains from untreated wild-type mice (i). Induction of LtR mRNA is weakly detected within the corpus
callosum of mice treated for 3 weeks (ii), and robust induction of LtR is seen in the same regions in brains from mice treated for
5 weeks (iii). C, Microscopic examination of the same brain sections shows LtR expression is highest in regions and time points
with a large accumulation of microglia/macrophages. In i–vi, nuclei are visualized by hematoxylin (blue) and LtR expression by
33P-labeled riboprobes (dark grains within the emulsion). In i–iii, microglia, blood vessels, and macrophages are visualized with
tomato lectin (brown), whereas in iv–vi, astrocytes are visualized with GFAP antibodies (brown). In all panels, the focal plane is
optimized to visualize the riboprobe-induced grains within the emulsion.
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Because the membrane-bound ligand
LIGHT (Granger and Ware, 2001) has the
ability to interact with LtR, at least in the
periphery, we analyzed LIGHT expression
levels by RT-PCR during cuprizone treat-
ment. Although LIGHT is found at high
levels in the control spleen and thymus,
negligible levels were found in the brains
of untreated or cuprizone-treated mice
(Fig. 2A). In addition, LIGHT is not regu-
lated by the presence of LtR because mice
lacking LtR express similar levels of
LIGHT in the brain (Fig. 2B). This sug-
gests that LIGHT does not play a signifi-
cant role during cuprizone-induced in-
flammation. This is similar to the
conclusion reached by others using the
EAE model (Gommerman et al., 2003).
Delayed demyelination in LtR/ mice
To analyze the role of LtR in demyelina-
tion, cuprizone-treated LtR/ mice
were compared with treated wild-type
mice. A significant delay in demyelination
was observed in the LtR/ mice relative
to wild-type mice, as assessed by LFB–PAS
staining (Fig. 3A). These data indicate that signaling through
LtR exacerbates the inflammatory demyelinating process. This
delay could be seen as early as 3 weeks ( p  0.02) of cuprizone
treatment but was most pronounced at 3.5 weeks ( p  0.01) and
4 weeks ( p  0.001) of treatment and is clearly revealed by rep-
resentative LFB–PAS images of wild-type and LtR/ mice at 4
weeks of treatment (Fig. 3B). Because the delay in demyelination
in LtR/ mice is similar to the delay in demyelination seen in
Lt/ mice (Plant et al., 2005), this suggests that membrane-
bound Lt signaling through the LtR is involved in the demy-
elination process.
Delayed remyelination in LtR/ mice
The ability of mature oligodendrocytes to remyelinate the corpus
callosum was studied in LFB–PAS-stained paraffin sections from
wild-type and LtR/ mice. Modest but significant differences
in remyelination were observed between wild-type and LtR/
mice at 7 weeks ( p  0.001) and 10 weeks ( p  0.02) (Fig. 3A).
By 12 weeks, LtR/ mice have remyelinated to the same extent
as wild-type controls ( p  0.11). These differences during remy-
elination are 0.5 on the scale of severity of demyelination,
whereas differences seen in studies of TNF/ versus wild-type
mice were 1.5 on the scale (Arnett et al., 2001) and persisted up
to 14 weeks (our unpublished data). We conclude that, although
remyelination appears to be transiently delayed in LtR/ mice,
it eventually occurs.
Delayed loss of oligodendrocytes in LtR/ mice
during demyelination
To verify that the delay in demyelination observed by LFB–PAS is
accompanied by changes in oligodendrocyte number, we per-
formed immunohistochemistry for GST, a marker shown to be
specific for mature myelinating oligodendrocytes (Tansey and
Cammer, 1991) on adjacent paraffin sections. GST cells at the
midline corpus callosum were quantitated. Abundant oligoden-
drocytes were detected in both wild-type and LtR/ untreated
mice. As has been shown previously, the number of GST oli-
godendrocytes is dramatically reduced after 3 weeks of cuprizone
treatment (Mason et al., 2000; Arnett et al., 2002). This represents
an actual loss of oligodendrocytes because these cells exhibit in-
creased apoptosis rather than a simple loss of the marker (Arnett
et al., 2002). However, after 3.5 weeks of treatment, significantly
more oligodendrocytes were present in LtR/ mice compared
with wild-type mice ( p  0.01) (Fig. 4A,B), indicating a delay in
the death of oligodendrocytes in the absence of LtR. No differ-
ence in oligodendrocyte number was found between wild-type
and LtR/ mice at 4 weeks. These data are complementary to
the LFB staining results (Fig. 3A). By 5 weeks of cuprizone treat-
ment, few GST oligodendrocytes were detected in the corpus
callosum of wild-type and LtR/ mice. This data point is con-
sistent with the severe demyelination shown in Figure 3A for both
mouse strains at the 5 week time point.
Normal oligodendrocyte repopulation of corpus callosum in
LtR/ mice during remyelination
Although oligodendrocytes were rarely detected in the corpus
callosum of 5 week cuprizone-treated mice, just 1 week after the
removal of cuprizone (7 weeks), the corpus callosum was repop-
ulated to 	75% of the original number of mature oligodendro-
cytes. No difference in oligodendrocyte number was observed
between wild-type and LtR/ mice. By week 10, the number of
mature oligodendrocytes residing in the corpus callosum recov-
ered to pretreatment levels in both wild-type and LtR/ mice.
Thus, LtR is not required for oligodendrocyte progenitor pro-
liferation and maturation during the remyelination phase. This
differs from our previous study that demonstrated a profound
role for TNF and TNFRII in the proliferation of oligodendro-
cyte progenitors (Arnett et al., 2001).
Recruitment of microglia/macrophage is not changed in
LtR/ mice
Cuprizone induces a chronic inflammatory state in the brain
including the recruitment of activated microglia and macro-
phages to the sites of insult (Matsushima and Morell, 2001). Par-
Figure 2. PCR analysis of LIGHT during cuprizone treatment. A, RT-PCR for the ligand LIGHT was performed on cDNA from
untreated and cuprizone-treated wild-type mouse brain. As controls, untreated thymus and spleen were analyzed. Representa-
tive results show that very low levels of LIGHT mRNA exist in the untreated and cuprizone-treated brain. B, RT-PCR on wild-type
(WT) and LtR/ untreated (untrt) and treated brain cDNA demonstrate that the lack of LtR has no effect on LIGHT RNA levels.
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affin sections from LtR/ and wild-type mice were stained
with the lectin RCA-1, and microglia/macrophages at midline
corpus callosum were quantitated. We found no difference be-
tween LtR/ and wild-type mice in the recruitment of acti-
vated microglia/macrophage during the demyelination or remy-
elination phases of this model (Fig. 4C).
Inhibition of functional LtR reduces demyelination
It has been well established that mice lacking LtR from birth
have significant developmental abnormalities (Futterer et al.,
1998). Functional inhibition of LtR in wild-type mice is possible
using a fusion decoy protein and has been shown to affect the
time course of EAE as well as prevent disease relapse (Gommer-
man et al., 2003). To assess the validity of our findings in LtR/
mice demonstrating a detrimental role for LtR during
cuprizone-induced demyelination, we treated C57BL/6 mice
with either LtR– hIg fusion decoy protein
or control human IgG during cuprizone
treatment. LtR– hIg was shown previ-
ously to effectively inhibit Lt–LtR sig-
naling (Gommerman et al., 2003). Mice
were pretreated with either LtR– hIg or
control human Ig 1 d before start of the
cuprizone (day 1) and weekly thereafter
by intraperitoneal injection (5 mg/kg) and
were maintained on an ad libitum diet of
0.2% cuprizone for 3.5 weeks (Fig. 5A).
Mice were then perfused, and paraffin
brain sections were stained with LFB–PAS
to assess the extent of demyelination at the
midline corpus callosum. Mice treated
with control human Ig were significantly
more demyelinated than mice that re-
ceived the LtR– hIg inhibitor ( p  0.02)
(Fig. 5B,Ci–Civ). Immunohistochemistry
for MBP confirmed the increase of myelin-
ated fibers in mice treated with LtR– hIg
relative to mice treated with control hu-
man Ig. In conclusion, demyelination in
cuprizone-treated mice can be signifi-
cantly delayed by inhibition of LtR. This
is similar to the effect observed in the EAE
disease models using both mice and rats
(Gommerman et al., 2003). Our data dem-
onstrates that LtR– hIg can reduce demy-




Because our goal is to enhance the devel-
opment of a therapeutic treatment for de-
myelinating disease, we investigated the
ability of LtR–Ig to alter the extent of re-
myelination after significant demyelina-
tion had already occurred. To investigate
the role of LtR in the process of remyeli-
nation, C57BL/6 mice were treated with
cuprizone for 6 weeks. This period of cu-
prizone treatment reproducibly results in
complete demyelination in all mice stud-
ied to date, including the wild-type
C57BL/6 mice (Arnett et al., 2001; Plant et
al., 2005). Because of the concern that human Fc might elicit an
immune response in this prolonged experiment, a fusion protein
consisting of LtR–mIg was used in these studies. After 5 weeks
plus 2 d of cuprizone treatment and weekly thereafter, mice were
injected intraperitoneally with either LtR–mIg or control
mouse IgG-1. Cuprizone treatment was halted at the 6 week time
point, and mice were returned to normal chow (Fig. 6A). Mice
were killed after 10 weeks, and LFB-stained sections were ana-
lyzed as described above. Remarkably, mice treated with LtR–
mIg showed significantly enhanced remyelination ( p  0.007)
relative to mice treated with the control mouse Ig as measured by
LFB staining (Fig. 6B,Ci–Civ). Additionally, immunohistochem-
istry for MBP confirmed increased remyelination in mice treated
with LtR–mIg compared with control mouse Ig-treated mice
(Fig. 6Cv,Cvi). The number of mature oligodendrocytes within
the corpus callosum at 10 weeks was also quantitated. GST-
Figure 3. Time course of demyelination and remyelination in LtR/ and wild-type mice. A, LFB–PAS-stained paraffin
sections were graded on a scale from 0 (normal myelination) to 3 (complete demyelination) by three double-blinded investiga-
tors. Each circle represents an individual mouse: open circles, C57BL/6 wild-type (Wt); filled circles, LtR/ mice. Horizontal
lines indicate the median score of each group. Significant differences in demyelination were seen between wild-type and
LtR/ mice at 3 weeks ( p  0.02), 3.5 weeks ( p  0.01), and 4 weeks ( p  0.001). Significant differences during
remyelination were detected at 7 weeks ( p  0.001) and 10 weeks ( p  0.02). B, Representative LFB–PAS pictures at 4 weeks
of treatment demonstrate the delay in demyelination in LtR/ mice (ii) compared with wild-type mice (i). Higher-
magnification images of the corpus callosum of LtR/ (iv) and wild-type (iii) mice demonstrate the lack of myelinated fibers
and increased inflammation in wild-type mice during demyelination.
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positive oligodendrocytes were modestly
more prevalent in the corpus callosum of
LtR–mIg-treated mice compared with
control mouse Ig-treated mice, and this
difference is statistically significant ( p 
0.04) (Fig. 6Cvii,Cviii). In conclusion, re-
myelination in cuprizone-treated mice
was significantly enhanced by posttreat-
ment with an inhibitor of LtR signaling.
Discussion
The results of our study demonstrate an
exacerbatory role for LtR in cuprizone-
induced oligodendrocyte death and demy-
elination. Furthermore, they show a bene-
ficial role of inhibitory LtR–Ig proteins in
both the demyelination and remyelination
phases of this model. Initially, our com-
parison of LtR/ and wild-type mice
demonstrates a strong exacerbatory role
for LtR during the demyelination phase,
suggesting LtR as a possible therapeutic
target for treating demyelinating disor-
ders. However, the moderate delay ob-
served in LtR/ mice during remyelina-
tion raised concerns regarding the
potential efficacy of using LtR inhibitors
to treat such disorders. Because of the se-
vere developmental abnormalities in
LtR/ mice, it was necessary to directly
analyze LtR inhibition in mice with an
otherwise functional immune system and
without the developmental abnormalities
seen in LtR/ mice. The most impor-
tant result of this study is the significant
delay in demyelination and acceleration of
remyelination induced by LtR–Ig treat-
ment of wild-type mice. The latter was ob-
served in a posttreatment paradigm (Fig.
6). Despite the fact that mice exhibited
complete demyelination at the initiation
of posttreatment, LtR–mIg significantly
enhanced remyelination relative to treat-
ment with control mouse Ig.
We recently reported that the presence
of Lt exacerbated demyelination induced
by cuprizone treatment (Plant et al., 2005).
We further showed that the lack of Lt did
not alter the course of remyelination or the
proliferation of oligodendrocyte progeni-
tors during the remyelination phase of the
cuprizone model. Lt can function as a
homotrimeric molecule signaling through
the TNF receptors, as well as a heterotri-
meric molecule with Lt to signal through
the LtR. The role of TNF receptors in the
cuprizone model has been analyzed previ-
ously (Arnett et al., 2001), but the role of
LtR in this model was unknown before
this study.
Studies to assess the role of LtR in normal or pathological
states involving the CNS are limited. Using the Theilers murine
encephalomyelitis virus model of demyelination, it has been
shown that Lt and LtR are important for viral clearance and
the prevention of demyelination within the CNS, but this role is
primarily mediated by functional cytotoxic T cells, which require
Lt and LtR for their development (Lin et al., 2003). Specific
Figure 4. Delayed loss of mature oligodendrocytes during demyelination in LtR/ mice. A, Mature oligodendrocytes were
detected at midline corpus callosum of wild-type and LtR/ brains by GST immunohistochemistry. More GST  cells were
found in LtR/ mice compared with wild-type mice at 3 weeks ( p  0.09) (wild-type, gray bars; LtR/, black bars).
Significantly more GST  cells were found in LtR/ mice at 3.5 weeks ( p  0.03), although no differences in oligodendro-
cytes were found at 4 and 5 weeks of cuprizone treatment. After the removal of cuprizone, no differences in oligodendrocyte
repopulation of the corpus callosum were observed between wild-type and LtR/ mice. B, Representative pictures of GST 
cells from wild-type and LtR/ mice at 3 and 3.5 weeks of cuprizone treatment. C, Microglial/macrophage accumulation at
midline corpus callosum is unaffected by LtR. Microglia/macrophages were detected by RCA-1 lectin staining of paraffin sections
from wild-type and LtR/ mice during demyelination and remyelination time points. No significant difference in numbers of
RCA-1  cells was observed between wild-type and LtR/ mice at any time point.
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LtR pathway inhibitors administered in the EAE model revealed
a detrimental role of Lt–LtR signaling in demyelination, al-
though the major cellular players in this model are also T cells
(Gommerman et al., 2003).
In contrast to the above-mentioned disease models,
cuprizone-induced demyelination is not a T-cell-mediated event.
T cells are not prevalent during cuprizone-induced demyelina-
tion, and the onset of demyelination and remyelination is similar
in recombination activating gene RAG-1/ mice that lack T and
B cells (Arnett et al., 2001; Matsushima and Morell, 2001). Al-
though the CD4 T-cell-mediated EAE models have provided
significant insight, they have not always had predictive value for
MS therapies. Furthermore, there is evidence to suggest that MS
is not strictly a CD4 Th1-mediated disease (Lassmann and Ran-
sohoff, 2004), and some demyelinating lesions can be found in
the brain that do not coincide with T-cell infiltration but are
marked by glial infiltrates (Lucchinetti et al., 2000; Peterson et al.,
2001; Barnett and Prineas, 2004). The demyelinating lesions in
the cuprizone model of demyelination are
also characterized by massive microglia/
macrophage and astrocyte infiltrates with-
out evidence of T cells and thus effectively
mimic this subtype of MS lesion. Strik-
ingly, in this report we also find LtR up-
regulation primarily in the corpus callo-
sum in which massive inflammation and
demyelination is consistently observed
(Fig. 1B). By in situ hybridization, LtR
was localized to areas enriched for acti-
vated microglia/macrophages (Fig. 1C),
although some expression is also found in
astroglial-enriched regions, suggesting
that LtR on glial cells actively participates
in inflammation and demyelination dur-
ing cuprizone treatment. The fact that
mice lacking functional LtR show de-
layed onset of demyelination reinforces
this possibility.
In a previous publication, we used an
antibody against Lt to unequivocally
demonstrate Lt expression by astrocytes
in the inflamed corpus callosum of
cuprizone-treated mice (Plant et al.,
2005). This result coupled with the present
finding that microglia are a major source
of LtR expression suggests that Lt–
LtR signaling between astrocytes and mi-
croglia is a primary mediator in the in-
flammatory demyelinating process that
occurs during cuprizone treatment. In ad-
dition to Lt, LtR interacts with the
membrane-bound ligand LIGHT. LIGHT
has been studied to a lesser extent but
appears to be localized primarily to T cells,
immature dendritic cells, granulocytes,
and monocytes (Gommerman and
Browning, 2003). We show that LIGHT is
present at very low to undetectable levels
in the brain, and its expression level is not
altered by the presence of LtR or by cu-
prizone treatment (Fig. 2). These data sug-
gest a scenario in which the Lt produced
by activated astrocytes binds and activates
LtR on microglia/macrophages. Because Lt is known to signal
through LtR in a heterotrimeric membrane-bound complex
with Lt and not in the soluble Lt form (Ware et al., 1995), this
interaction likely requires cell-to-cell contact at the site of inflam-
mation and demyelination. The present study indicates that glial-
derived Lt–LtR signaling plays an important role in the de-
myelination process. Considering the large numbers of microglia
and astrocytes that infiltrate the corpus callosum from 3– 6 weeks
of cuprizone treatment, this cell– cell interaction is highly plausi-
ble (Hiremath et al., 1998; Matsushima and Morell, 2001).
Our data obtained in LtR/ mice indicate that LtR has a
significant exacerbatory effect on demyelination and a potentially
modest beneficial effect during remyelination. This result is sim-
ilar to our previous findings using Lt/ mice with respect to
demyelination, but Lt/ mice remyelinated normally (Plant et
al., 2005). There is evidence that mice lacking LtR from birth
have significant developmental abnormalities; LtR/ mice
lack mesenteric lymph nodes, Peyer’s patches, and colon-
Figure 5. Therapeutic inhibition of LtR significantly delays demyelination. A, C57BL/6 mice were treated with 0.2% cupri-
zone for 3.5 weeks. Mice received weekly injections (indicated by small arrows) of either LtR– hIg or control human Ig beginning
at day 1 of cuprizone treatment. B, Significant differences in demyelination were observed between LtR– hIg-treated and
control human Ig-treated mice after 3.5 weeks of cuprizone treatment ( p  0.02). LFB–PAS-stained paraffin sections were
graded on a scale of 0 (normal myelination) to 3 (complete demyelination) by three double-blinded investigators. Each circle
represents an individual mouse: open circles, control human Ig-treated mice; filled circles, LtR– hIg-treated mice. Horizontal
lines indicate the median score of each group. C, Representative LFB–PAS pictures at 3.5 weeks of treatment demonstrate the
delay in demyelination in control human Ig-treated mice (i) compared with LtR– hIg-treated mice (ii). High-magnification
images of the corpus callosum of control human Ig-treated mice (iii) and LtR– hIg-treated mice (iv) demonstrate the lack of
myelinated fibers and increased inflammation in control human Ig-treated mice during demyelination. Immunohistochemistry
for MBP confirmed the presence of more myelinated fibers in LtR– hIg-treated mice (vi) compared with control human Ig-
treated mice (v).
Plant et al. • Therapeutic Lt–LtR Inhibition in Demyelination J. Neurosci., July 11, 2007 • 27(28):7429 –7437 • 7435
associated lymphoid tissues. In addition,
T- and B-cell segregation is lost, follicular
dendritic cell networks are not defined in
the spleen, and antibody affinity matura-
tion is defective (Futterer et al., 1998). It is
known that LtR exerts control over che-
mokine and cytokine synthesis (Chin et
al., 2003), although the full impact on the
CNS is not known. Furthermore, natural
killer cells in LtR/ mice do not have
surface expression of the NK1.1 receptor
attributable to the proximity of the encod-
ing gene and the Ltbr gene (Wu et al.,
2001). For these reasons, it is possible that
our results with LtR/ mice do not ac-
curately reflect the true role of LtR in in-
flammation and demyelination attribut-
able to the developmental abnormalities
found in LtR/ mice.
LtR–Ig inhibitors have been success-
ful in reducing disease severity in the EAE
model of demyelination (Gommerman et
al., 2003). The same inhibitory fusion Igs
were used in conjunction with the cupri-
zone model here to analyze the effect of
functional LtR inhibition in wild-type
C57BL/6 mice. Compared with human Ig
protein-treated mice, LtR– hIg-treated
mice exhibited a significant delay in demy-
elination after 3.5 weeks of cuprizone
treatment (Fig. 5B,C), providing support
for the Gommerman et al. study (2003).
Variations observed between wild-type
mice in these studies are within the normal
range for the cuprizone model (Figs. 3, 5,
6), and, for this reason, wild-type animals
are included in each experiment. How-
ever, this study was undertaken using an
EAE model, and it was postulated that the
effects of LtR–Ig were mediated primar-
ily by its action on T cells. Because cupri-
zone is not a T-cell-mediated model, our
study represents the first evidence that
LtR inhibition effects pathology other
than that induced by T cells. The role of
LtR in remyelination had not been ana-
lyzed before this study. Mice treated with
LtR–mIg showed an increased number of
GST oligodendrocytes in the corpus
callosum and were able to remyelinate more efficiently as deter-
mined by LFB and MBP staining (Fig. 6B,C). Thus, by inhibiting
Lt–LtR signaling, both proliferation and maturation of oligo-
dendrocyte progenitor cells were enhanced. The mechanism of
action of LtR–Ig is unclear but deserving of in depth analysis
because it may unveil important regulatory events that lead to
remyelination.
In conclusion, we hypothesize that LtR on glial cells, likely
through direct interaction with membrane Lt heterotrimers
on astrocytes, contribute to exacerbated demyelination and im-
pede remyelination. This study bodes well for the use of LtR–Ig
as a candidate biological therapy in demyelinating disorders, be-
cause inhibition has dual beneficial outcomes, both delaying de-
myelination and promoting remyelination. This provides a sub-
stantial rationale to explore LtR inhibitors for treating
demyelinating disorders. The pharmacologic inhibition of
TNF, which once was believed to be strictly proinflammatory,
was detrimental to MS patients and resulted in symptom exacer-
bation (van Oosten et al., 1996; The Lenercept Multiple Sclerosis
Study Group and The University of British Columbia MS/MRI
Analysis Group, 1999; Arnett et al., 2001). Since the realization
that TNF has dual roles, being both detrimental during demy-
elination but required for oligodendrocyte progenitor prolifera-
tion and remyelination (Liu et al., 1998; Arnett et al., 2001; Kas-
siotis and Kollias, 2001), the results of the clinical studies are
easier to interpret. In contrast, we find that inhibition of Lt–
LtR signaling is beneficial during both demyelination and re-
myelination, thus making lymphotoxin inhibitors better candi-
Figure 6. Therapeutic inhibition of LtR significantly enhances remyelination in a posttreatment paradigm. A, C57BL/6 mice
were treated with 0.2% cuprizone for 6 weeks and allowed to remyelinate for 4 weeks before they were killed. Mice received
weekly injections of either LtR–mIg or control mouse Ig beginning 5 weeks plus 2 d after the start of cuprizone treatment (the
approximate height of demyelination), as indicated by small arrows. B, Remyelination was enhanced on inhibition of LtR
signaling. LFB–PAS-stained paraffin sections were graded on a scale of 0 (normal myelination) to 3 (complete demyelination) by
three double-blinded investigators. Each circle represents an individual mouse: open circles, control mouse Ig-treated mice; filled
circles, LtR–mIg-treated mice. Horizontal lines indicate the median score of each group. Significant enhancement of remyeli-
nation was observed in LtR–mIg-treated mice compared with mice treated with control mouse Ig ( p  0.007). C, Represen-
tative LFB–PAS pictures at 10 weeks demonstrate the enhanced remyelination in LtR–mIg-treated mice (ii) compared with
control mouse Ig-treated mice (i). High-magnification images of the corpus callosum of LtR–mIg-treated (iv) and control
mouse Ig-treated (iii) mice demonstrate the lack of myelinated fibers and greater inflammation in control mouse Ig-treated mice
during remyelination. Immunohistochemistry for MBP confirmed enhanced remyelination in LtR–mIg-treated mice (vi) com-
pared with control mouse Ig-treated mice (v). Representative GST-immunostained images of the corpus callosum demonstrat-
ing more oligodendrocytes in mice treated with LtR–mIg inhibitor (viii) than mice treated with the control mouse Ig (vii).
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date biological therapies for the control of inflammatory
demyelinating disorders.
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